Grandbrothers/iStock Editorial via Getty Images
Grandbrothers/iStock Editorial via Getty Images
Early August, ELDN announced that the FDA greenlighted a mid-stage trial for tegoprubart as a treatment to prevent organ rejection in patients who underwent a kidney transplant.